Inhaled Insulin: One Giant Leap for MannKind 5 comments
-
Font Size:
-
Print
- TweetThis
Billionaire Alfred Mann must not have liked watching stock in the company bearing his name fall to another new low Monday in the wake of Eli Lilly giving up on inhaled insulin.
Although Alkermes could presumably find another corporate partner to try to rescue its "AIR Insulin" product, MannKind (MNKD) is the only company left still actively developing an inhalable form of diabetic insulin. And so Monday afternoon, MannKind put out a press release with the header, "MannKind Corporation Response to Recent Market Events", reaffirming its commitment to the device. "MannKind is absolutely commited to the continued development of its lead development product, Technosphere Insulin," the statement says.
The release goes on in detail about the product's safety and efficacy. The company is testing Technosphere on more than 5,000 people and more than 2,000 of them are in a two-year study to specifically measure the impact, if any, on lung function.
Mr. Mann is putting his money where his mouth is and has reportedly invested about a billion dollars from his own bank account in the device. And the company says it has the wherewithal to see it through.
"Currently, MannKind has sufficient financial resources to fund these programs and others (Technosphere and other development pipeline products) through the end of 2009."
And despite the fact that drug giants Lilly (LLY), Pfizer (PFE)and NovoNordisk (NVO) have all recently gotten out of the inhalable insulin business the release says: "It is MannKind's intention to bring these treatments to patients in collaboration with a leading pharmaceutical partner who shares a commitment to improving the lives of people with diabetes and who understands the difference between MannKind's products and other diabetes therapies on the market today."
MannKind still closed at a new low of $4.99, but well above its intra-day low of $4.25.
Related Articles
|




























This article has 5 comments:
Thanks in advance
$4.99 is too expensive. In fairness, this stock shouldn't be listed in any proper stock exchange. Instead, it should be listed in pinksheet or OTC.
The website link is to a CNBC interview with the Mann himself. In it, the self-made pharma-billionaire says Technosphere is technologically superior to the failed inhalables in the way it delivers insulin and offers significant clinical advantages to current insulin therapies, allowing the patient to manage his or her blood sugar levels more effectively without having to stick needles in the skin. As he says, it changes the whole paradigm of therapy. Exubera's failure and the other companies withdrawals simply eliminates potential competition. When Al Mann again proves he's got the Midas Touch, like in every other venture he's ever attempted, people are going to wish they'd bought when it was this low.
Full disclosure, I'm invested.